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OBJECTIVE—Polymorphisms in the adiponectin gene
(ADIPOQ) have been associated with type 2 diabetes and dia-
betic nephropathy in type 1 diabetes, in mostly European-derived
populations.
RESEARCH DESIGN AND METHODS—A comprehensive as-
sociation analysis of 24 single-nucleotide polymorphisms (SNPs)
in the adiponectin gene was performed for type 2 diabetes and
diabetic nephropathy in African Americans.
RESULTS—The minor allele (A) in a single SNP in intron 1
(rs182052) was associated with diabetic nephropathy (P 
0.0015, odds ratio [OR] 1.37, CI 1.13–1.67, dominant model) in an
African American sample of 851 case subjects with diabetic
nephropathy and 871 nondiabetic control subjects in analyses
incorporating adjustment for varying levels of racial admixture.
This association remained signiﬁcant after adjustment of the data
for BMI, age, and sex (P  0.0013–0.0004). We further tested this
SNP for association with longstanding type 2 diabetes without
nephropathy (n  317), and evidence of association was also
signiﬁcant (P  0.0054, OR 1.46, CI 1.12–1.91, dominant model)
when compared with the same set of 871 nondiabetic control
subjects. Combining the type 2 diabetes and diabetic nephropa-
thy samples into a single group of case subjects (n  1,168)
resulted in the most signiﬁcant evidence of association (P 
0.0003, OR 1.40, CI 1.17–1.67, dominant model). Association tests
between age at onset of type 2 diabetes and the rs182052
genotypes also revealed signiﬁcant association between the
presence of the minor allele (A/A or A/G) and earlier onset of
type 2 diabetes.
CONCLUSIONS—The SNP rs182052 in intron 1 of the adiponec-
tin gene is associated with type 2 diabetes in African Americans.
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T
ype 2 diabetes and diabetic nephropathy are
more prevalent among African Americans than
European Americans, even when taking into
consideration ethnic differences in socioeco-
nomic status, prevalence and severity of hypertension, and
access to adequate health care (1–3). Studies of African
American families with type 2 diabetes (4) or diabetic
nephropathy (5) have revealed clustering of both diseases,
indicating a genetic component to susceptibility. Genome
scans in families have supported a genetic contribution to
susceptibility to type 2 diabetes and diabetic nephropathy
in African Americans (4,6).
Plasma adiponectin levels are inversely correlated with
diabetes and insulin resistance (7,8). In contrast, plasma
adiponectin has been shown to be increased in patients
with kidney disease (9), and studies suggest that increased
adiponectin concentration is a predictor of subsequent
kidney disease (10).
Adiponectin gene (ADIPOQ) polymorphisms have been
implicated in type 2 diabetes (11) and type 1 diabetic
nephropathy (12,13). Few studies have addressed genetic
variants in adiponectin and association with diabetes in
Africans (14) or African Americans (15). This second
report in African Americans noted several differences
between European-derived samples and African Ameri-
cans regarding associations between ADIPOQ polymor-
phisms and body composition and lipid phenotypes
highlighting potential ethnic differences in the adiponectin
gene and the importance of investigating variants in this
gene in African Americans.
Given the paucity of studies on adiponectin gene poly-
morphisms and type 2 diabetes or diabetic nephropathy in
African Americans and the high risk of these diseases
in this population, a thorough interrogation of this gene in
African Americans was warranted. We tested 24 single-
nucleotide polymorphisms (SNPs) in the adiponectin gene
for association with type 2 diabetes and diabetic nephrop-
athy in a large collection of African Americans residing in
the southeastern U.S.
RESEARCH DESIGN AND METHODS
Case subjects included 851 unrelated African Americans with type 2 diabetes–
associated end-stage renal disease (ESRD) from dialysis centers in Winston-
Salem, Greensboro, and Hickory, NC. All diabetic nephropathy case subjects
had ESRD and were on dialysis at the time of recruitment. Diabetes was
considered to be the primary cause of nephropathy if subjects developed
diabetes after the age of 35 years and diabetes was present 5 years before
initiation of renal replacement therapy and/or in the presence of diabetic
retinopathy or proteinuria exceeding 500 mg/24 h. An additional 317 unrelated
African Americans with type 2 diabetes and no renal disease, and 871
nondiabetic unrelated control subjects were recruited from medical clinics,
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DIABETES, VOL. 58, FEBRUARY 2009 499churches, and health fairs in North Carolina. Diabetic subjects lacking
nephropathy had diabetes for 10 years with a spot urine albumin-to-
creatinine ratio 30 mg/g and serum creatinine concentration 1.5 mg/dl in
men or 1.3 mg/dl in women. Individuals were actively receiving treatment
with oral hypoglycemic agents and/or insulin. Nondiabetic control subjects
were self-reported African Americans born in the southeast, age 18 years,
who denied a personal history of diabetes or a personal or family history of
kidney disease in ﬁrst-degree relatives. Each participant provided 40 ml blood
for DNA isolation. DNA was isolated using an AutoPure LS automated DNA
extraction robot (Gentra Systems, Minneapolis, MN). Recruitment and sample
collection procedures were approved by the Institutional Review Board at
Wake Forest University, and all subjects provided written informed consent.
SNP genotyping. A total of 24 SNPs were genotyped in 1,168 African
American case subjects (851 with diabetic nephropathy and 317 with type 2
diabetes lacking nephropathy) and 871 nondiabetic control subjects. SNPs
were chosen based on their ability to capture genetic information for African
(Yoruban) and European (CEU) populations in Hapmap (www.hapmap.org)
using Tagger (Haploview [16]). Tagged SNPs had a minor allele frequency
0.05 and captured an inter-SNP r
2 value 0.8 for known polymorphisms in
the region. Three SNPs, rs17300539, rs4632532, and rs266729, were included
based on previous association with type 1 diabetic nephropathy or insulin
resistance syndrome phenotypes (13,17). A total of 34 SNPs were initially
chosen for analysis. Two SNPs failed design, six SNPs could not be incorpo-
rated into a multiplex, and two SNPs were eliminated because of low
genotyping efﬁciency. The genotyped SNPs captured at least 64% of the
variation in the Yoruban HAPMAP sample. SNPs were genotyped using the
MassARRAY genotyping system (Sequenom, San Diego, CA). PCR primers
were designed using the MassARRAY Assay Design 3.4 Software (Sequenom).
All case and control subjects were genotyped at 70 admixture informative
markers (AIMs) to estimate the percentage of African ancestry for each
individual (18,19).
DNA sequencing. The associated SNP rs182052 was sequenced in 175
African Americans with diabetic nephropathy to verify the accuracy of the
genotype calls. The region was PCR ampliﬁed and products were puriﬁed and
directly sequenced using Big Dye Ready Reaction Mix on an ABI3730xl
sequencer (Applied Biosystems, Foster City, CA). Sequence data were visual-
ized using Sequencher Software version 4.6 (GeneCodes Corporation, Ann
Arbor, MI).
Statistical analysis. Biometric data were compared using a Kruskal-Wallis
one-way ANOVA on Ranks (SigmaStat; Systat Software, San Jose, CA) with a
Dunn’s method multiple comparison test. Age at onset of type 2 diabetes in the
diabetic nephropathy and type 2 diabetic case subjects was compared using a
Mann-Whitney rank-sum test (SigmaStat). Each SNP was tested for departures
from the Hardy-Weinberg equilibrium using the 
2 goodness-of-ﬁt test in the
statistical analysis program SNPGWA (www.phs.wfubmc.edu) (20). Tests for
genotypic association were performed on each SNP individually using
SNPGWA-ADMIX, a component of the SNPGWA program that includes the
capability to perform association calculations adjusting for covariates. Geno-
typic association reported here is for analyses incorporating adjustment for
ancestry proportions. The primary inference is based on the 2 d.f. global test
of genotypic association. If signiﬁcant, then the individual genetic models
(dominant, additive, and recessive) were examined for context. This is
consistent with the Fisher’s protected least signiﬁcant difference multiple
comparisons procedure. Percentage of African ancestry was computed from
70 admixture informative markers using the program Frappe (18,19). The
inﬂuence of other possible covariates (age, BMI, and sex) on evidence of
association was tested using SNPGWA-ADMIX. Two-SNP haplotype analysis
was completed using the program Dandelion (www.phs.wfubmc.edu). Link-
age disequilibrium was calculated as deﬁned by Gabriel et al. (21) with the
program Haploview (16).
We computed a series of Cox proportional hazards models and the
corresponding likelihood ratio statistics to test for associations between
adiponectin polymorphisms and age at type 2 diabetes onset for 1) diabetic
nephropathy case subjects, 2) type 2 diabetic (no nephropathy) case subjects,
and 3) type 2 diabetic and diabetic nephropathy case subjects combined.
Here, age at type 2 diabetes onset was computed for the above three
conditions and was contrasted with the age of nondiabetic control subjects at
time of enrollment; speciﬁcally, control subjects had “age at onset of type 2
diabetes” censored at age of enrollment. The hazards ratio (HR) and corre-
sponding 95% CI was computed as exp( ˆ) and exp [ ˆ  1.96  SE ( ˆ)],
respectively. Tests for association and the estimates for the hazards ratio were
computed without covariate adjustment and adjusting for sex, BMI, and
admixture estimates. As discussed above, the genetic models are deﬁned
relative to the minor allele frequency.
RESULTS
Descriptive data for participants are summarized in Table
1. Diabetic nephropathy and type 2 diabetic case subjects
were older and more were female compared with the
nondiabetic control subjects. Type 2 diabetic case subjects
had increased BMI compared with diabetic nephropathy
case subjects and nondiabetic control subjects. The aver-
age age at type 2 diabetes onset for case subjects with
diabetic nephropathy was less than that of case subjects
with type 2 diabetes without nephropathy.
A total of 24 SNPs in the adiponectin gene were suc-
cessfully genotyped in diabetic nephropathy case subjects
and nondiabetic control subjects. None of the SNPs de-
parted from the Hardy-Weinberg equilibrium after correc-
tion for multiple comparisons. Two SNPs, rs182052 and
rs3821799, showed evidence of association with diabetic
nephropathy (Supplemental Table 1, found in an online
appendix at http://dx.doi.org/10.2337/db08-0598). SNP
rs182052 was associated with diabetic nephropathy in the
2 d.f. test (P  0.002) and under the dominant model (P 
0.002, odds ratio [OR] 1.37; 95% CI 1.13–1.67) (Table 2).
SNP genotype calls for rs182052 were veriﬁed by direct
DNA sequence analysis in 175 case subjects with diabetic
nephropathy to ensure that the slight departure from
Hardy-Weinberg equilibrium in the case subjects was not
the result of erroneous genotyping. Genotypes observed
from DNA sequencing were 100% concordant with geno-
types generated from the Sequenom MassArray system.
The SNP rs3821799 was also associated (P  0.039) but did
not retain statistical signiﬁcance after adjusting for multi-
ple comparisons.
SNP rs182052 was associated with BMI and waist mea-
sures in Hispanic Americans in the Insulin Resistance and
Atherosclerosis (IRAS) Family Study (22). To ascertain
whether the association of rs182052 with diabetic ne-
phropathy reﬂected an association with BMI or other
phenotypes known to be associated with increased risk of
type 2 diabetes or diabetic nephropathy, genotypic asso-
ciation was evaluated with individual adjustments for BMI,
sex, and age at exam (Table 2) and showed little effect on
the evidence of association. We also tested association
after simultaneously adjusting for admixture, BMI, sex,
and age. Evidence of association between rs182052 and
TABLE 1
Demographic characteristics of African American cohort
n Age BMI % female
Age at onset of
type 2 diabetes
Age at onset of
ESRD
Nondiabetic control subjects 871 50.9  11.6 29.5  7.0 55.1
Diabetic nephropathy 851 61.8  10.0* 29.4  6.8 62.7 41.0  12.0 58.5  10.2
Type 2 diabetes (no nephropathy) 317 58.6  11.5* 32.9  7.1* 65.5 43.8  12.0
†
*Mean is signiﬁcantly different from nondiabetic subjects (P  0.05). †Mean is signiﬁcantly different (P  0.05) from the type 2 diabetes (no
nephropathy) case subjects.
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1.46, CI 1.15–1.86) under the dominant model.
To discern whether rs182052 was associated with ne-
phropathy or diabetes in our African American sample,
this SNP was tested for association in 317 African Ameri-
cans with longstanding type 2 diabetes without nephrop-
athy versus the 871 nondiabetic control subjects. This SNP
was associated with type 2 diabetes under the dominant
model (P  0.0054; OR 1.46, CI 1.12–1.91) after adjustment
for African ancestry proportions, and the association
remained signiﬁcant with adjustment for all four covari-
ates (P  0.0056, OR 1.54, CI 1.13–2.09) (Supplemental
Table 2). When evaluating all 1,168 African American
diabetic individuals (851 with diabetic nephropathy and
317 with type 2 diabetes without nephropathy), rs182052
remained associated with type 2 diabetes under the dom-
inant model (P  0.0003, OR 1.40, CI 1.17–1.67) with
adjustment for proportion of African ancestry (Table 2).
Individual and combined adjustment for African ancestry,
age, BMI, and sex did not signiﬁcantly alter this result. To
clarify whether the association was with type 2 diabetes
only or also with nephropathy, we tested rs182052 for
association between the two groups of case individuals:
diabetic nephropathy and type 2 diabetes lacking nephrop-
athy. There was no association detected (P  0.87, OR
0.98, CI 0.73–1.30), indicating that the rs182052 is associ-
ated with type 2 diabetes status and not nephropathy.
The linkage disequilibrium structure for the adiponectin
gene in African American nondiabetic control subjects is
shown in Supplemental Fig. 1. African Americans have one
large block at the 3 end of the gene and four smaller
blocks surrounding it. The associated SNP, rs182052, is
located in a small linkage disequilibrium block containing
one other known SNP, rs266729, and covering the
promoter.
A Cox proportional hazards model was used to deter-
mine the relative risk (RR) for early age at onset of type 2
diabetes for genotypes at the associated SNP, rs182052
(Table 3). Signiﬁcant risk for earlier onset of type 2
diabetes was detected under the dominant model (P 
0.0031–0.0002; RR 1.26–1.41) for the diabetic nephropathy
and type 2 diabetic case groups individually and when the
two groups were combined (diabetic nephropathy 	 type
2 diabetes). Signiﬁcant risk was also found with age at
onset of ESRD under the dominant model (P  0.0113; RR
1.20). RR increased when the data were adjusted for sex,
BMI, and admixture (P  0.0084; RR 1.21). Pearson’s
correlation coefﬁcient (r  0.56; P  0.001) indicated a
positive correlation between the age at onset of type 2
diabetes and the age at onset of ESRD, suggesting that
early age of onset of ESRD may depend on an early age of
onset of type 2 diabetes. We conﬁrmed this by calculating
the RR of age at onset of ESRD after adjustment for age at
onset of type 2 diabetes and saw no signiﬁcant risk (Table
3). When the survival distribution function is plotted
versus the age at onset of type 2 diabetes (Fig. 1),
individuals with the minor allele A (A/A or A/G genotypes)
have an earlier age at onset of type 2 diabetes compared
with individuals who are homozygous for the G allele (G/G
genotype).
DISCUSSION
We have evaluated association between adiponectin gene
polymorphisms and type 2 diabetes and diabetic nephrop-
athy in a large sample of African Americans. We observed
evidence of association between the rs182052 polymor-
phism in intron 1 in African Americans with type 2
diabetes. This evidence of association remained signiﬁcant
after adjustment for African ancestry, age, BMI, and sex. In
the fully adjusted models, the P value for association of
rs182052 with type 2 diabetes was 0.0005, a level of
signiﬁcance that survives even stringent Bonferroni adjust-
ment. Survival analysis revealed association between the
minor allele and earlier age at onset of type 2 diabetes.
Previous studies of association between adiponectin poly-
TABLE 2
Genotypic association with diabetic nephropathy and type 2 diabetes
Hardy-Weinberg
equilibrium Genotypic association




subjects PP OR CI P OR CI P OR CI
Diabetic nephropathy vs.
nondiabetic
Admixture 0.024 0.060 0.0019 0.0015 1.37 1.13–1.67 0.0393 1.16 1.01–1.34 0.6442 0.94 0.71–1.24
Age 0.0032 0.0009 1.49 1.18–1.89 0.0081 1.26 1.06–1.49 0.6225 1.09 0.78–1.53
BMI 0.0008 0.0004 1.46 1.19–1.80 0.0110 1.22 1.05–1.42 0.9334 0.99 0.73–1.34
Sex 0.0017 0.0013 1.38 1.13–1.67 0.0378 1.16 1.01–1.34 0.6330 0.93 0.70–1.24
Combined 0.0019 1.46 1.15–1.86 0.0114 1.25 1.05–1.49 0.5593 1.11 0.79–1.56
Type 2 diabetes 	 diabetic
nephropathy vs.
nondiabetic
Admixture 0.003 0.061 0.0003 0.0003 1.40 1.17–1.67 0.0196 1.17 1.03–1.33 0.5549 0.92 0.71–1.20
Age 0.0006 0.0002 1.50 1.21–1.86 0.0058 1.25 1.07–1.46 0.8796 1.02 0.75–1.40
BMI 0.0001 0.0001 1.47 1.21–1.79 0.0075 1.22 1.05–1.41 0.7473 0.95 0.72–1.27
Sex 0.0002 0.0002 1.41 1.17–1.69 0.0187 1.17 1.03–1.34 0.5110 0.92 0.70–1.19
Combined 0.0005 1.48 1.19–1.84 0.0088 1.24 1.06–1.45 0.8408 1.03 0.75–1.42
Genotypic association for rs182052 after individual adjustment for admixture, age, BMI, and sex in 851 type 2 diabetes 	 diabetic
nephropathy case subjects versus 871 nondiabetic control subjects and type 2 diabetes 	 diabetic nephropathy case subjects plus an
additional 317 type 2 diabetic (no nephropathy) subjects (total cases  1,168) versus the same 871 nondiabetic control subjects. Genotypic
association is also shown for all four covariates simultaneously (combined).
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have evaluated European-derived or Asian populations,
with only one study in non-European South Africans (14)
and one study with a small number of African Americans
(15). To our knowledge, this is the ﬁrst study that has
addressed adiponectin gene polymorphism associations
with type 2 diabetes and diabetic nephropathy in African
Americans.
In our case samples, allele frequencies of rs182052
deviated slightly from the Hardy-Weinberg equilibrium.
This may be the result of differing allele frequencies in the
European and African ancestral populations. In HapMap
(www.hapmap.org), the Yoruban population has a minor
allele frequency of 0.395 at this SNP, whereas the Euro-
pean population has a minor allele frequency of 0.353. This
difference underscores the importance of including adjust-
ment for African Ancestry in analyses of African American
populations. In our case subjects and control subjects, the
percentage of African ancestry was similar between the
two groups of case subjects and the control subjects (80 
10 to 82  10).
This study was well powered to detect associations
consistent with complex genetic traits with over 1,168
(combined) type 2 diabetes and diabetic nephropathy case
subjects and more than 871 nondiabetic control subjects.
With this large sample size, we had 80% power to detect
an odds ratio of 1.3–1.5 under the dominant model of
association within a range of minor allele frequencies
(0.1–0.3). While a number of the genotyped SNPs had low
minor allele frequencies (0.05) and would contribute to a
reduction in power, the associated SNP was relatively
common (minor allele frequency  0.348 in control sub-
jects) and the low P value contributes a high level of
conﬁdence in this association.
Previous studies have reported association between
adiponectin polymorphisms and type 2 diabetes (14,15,23–
26) and diabetic nephropathy (13). These studies have
primarily detected association with SNPs in the promoter
region (rs17300539 and rs266729) or in exons (rs22517766
and rs1501299). With our African American sample, we
have the ability to detect association with both type 2
diabetes and diabetic nephropathy. We tested three of
these SNPs (rs17300539, rs266729, and rs1501299) and
found no signiﬁcant evidence for association. That the
association in our African American collection is at a
different SNP is not unexpected. This may reﬂect ethnic
differences in adiponectin gene structure, as discussed by
Ukkola et al. (15) in their evaluation of African Americans
from the HERITAGE study. The lack of two distinct
linkage disequilibrium blocks in the adiponectin gene in
our African American sample, compared with that previ-
ously demonstrated in European-derived samples (27),
also supports this conclusion. In addition, Woo et al. (28)
identiﬁed nine SNPs in the adiponectin gene that had
signiﬁcantly different minor allele frequencies (P  0.001)
between African Americans and European Americans.
These genetic data are further supported by evidence that
African Americans have reduced plasma adiponectin con-
centrations than other ethnic groups (Europeans, Japa-
nese, and Pima Indians) (29). The potential for ethnic
differences in the adiponectin gene emphasizes the need to
study genetic associations in multiple populations, partic-
ularly African Americans.
Whereas association with type 2 diabetes has not been
previously reported with rs182052, this SNP has been
associated with BMI and waist measures in Hispanic
Americans in the Insulin Resistance and Atherosclerosis
Family Study (22). To ascertain whether the association
we observed was the result of type 2 diabetes and not
increased BMI, we adjusted for BMI in the association
analysis. The evidence of association remained signiﬁcant
after BMI adjustment, indicating that the difference in
adiposity between case subjects and control subjects is
not driving the association and that the mechanism is via
some other pathway. In addition, rs182052 is in the same
haplotype block as rs266729 (Supplementary Fig. 1) in
African Americans, an SNP with prior reports of associa-
tion with type 2 diabetes (11). Haplotype analysis of these
two SNPs revealed no association with type 2 diabetes or
diabetic nephropathy (Supplementary Table 3).
Woo et al. (28) and Heid et al. (27) have demonstrated
association between the minor allele of rs182052 (A) and
reduced levels of plasma adiponectin in European-derived
American adolescents and healthy Europeans, respec-
tively. In our study, individuals with the minor allele (A/A
or A/G genotypes) had earlier onset of type 2 diabetes. If
the minor allele is contributing to type 2 diabetes in our
samples by reduced levels of plasma adiponectin, this
TABLE 3
Survival analysis to estimate risk of early age at onset of type 2 diabetes and ESRD
Dominant Recessive Additive
P RR P RR P RR
Age at onset of type 2 diabetes
Diabetic nephropathy 0.0003 1.29 1.0000 1.00 0.0102 1.14
Type 2 diabetes 0.0031 1.41 0.9714 0.99 0.0338 1.19
Diabetic nephropathy 	 type 2 diabetes 0.0002 1.26 0.9217 1.01 0.0063 1.13
After adjustment
Diabetic nephropathy 0.0011 1.27 0.9391 0.99 0.0192 1.13
Type 2 diabetes 0.0034 1.42 0.7143 0.94 0.0507 1.17
Diabetic nephropathy 	 type 2 diabetes 0.0004 1.25 0.9878 1.00 0.0091 1.12
Age at onset of ESRD
Diabetic nephropathy 0.0113 1.20 0.1443 1.17 0.0098 1.14
After adjustment for sex, BMI, and admixture
Diabetic nephropathy 0.0084 1.21 0.1148 1.18 0.0063 1.16
After adjustment for age at onset of type 2 diabetes
Diabetic nephropathy 0.86 0.99 0.34 1.11 0.73 1.03
P values and RRs are reported for the dominant, additive, and recessive models both before and after adjustment for sex, BMI, and admixture
proportions. Analysis of age at onset of ESRD is also adjusted for age at onset of type 2 diabetes.
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demonstrated an association between hypoadiponectine-
mia and increased risk of type 2 diabetes (24,30). We do
not have serum adiponectin concentrations for the sub-
jects in our study; however, it would be interesting to
determine whether rs182052 contributes to plasma adi-
ponectin concentrations in our collection of African Amer-
icans. It should be noted that Woo et al. (28) detected no
association between rs182052 and plasma adiponectin
levels in a comparably sized sample of African American
adolescents.
A primary issue with the observations we have made is
whether the observed association reﬂects an association
between rs182052 and type 2 diabetes, diabetic nephrop-
athy, or both. We have sampled a relatively large number
of African American subjects with diabetic nephropathy
and a smaller collection with type 2 diabetes and no
nephropathy to attempt to ascertain whether this gene is
associated with nephropathy or diabetes. As the SNP was
associated in subjects with diabetic nephropathy and
subjects with type 2 diabetes lacking nephropathy, we
believe that the data are most consistent with the rs182052
variant contributing to type 2 diabetes susceptibility in
African Americans. This is supported by the Cox model’s
RR, which indicated increased risk for earlier age at onset
of type 2 diabetes. Additionally, we compared allele fre-
quencies of rs182052 between the diabetic nephropathy
case subjects (n  851) and the type 2 diabetic (no
nephropathy) case subjects (n  317) and observed no
evidence of association. Although this analysis has less
power than the initial case-control analysis, it does sup-
port our conclusion that rs182052 is associated with type 2
diabetes in African Americans.
We observed association between a variant in the adi-
ponectin gene and type 2 diabetes in African Americans.
This SNP, rs182052, has not previously been associated
with diabetes or diabetic nephropathy in other popula-
tions, although it has been associated with plasma adi-
ponectin levels. That other variants previously associated
with diabetes or diabetic nephropathy in Europeans were
not associated in our African American population empha-
sizes the potential that there are likely ethnic differences in
the linkage disequilibrium structure of the adiponectin
gene.
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